Halozyme Therapeutics’ (HALO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research report report published on Tuesday,Benzinga reports. The firm currently has a $95.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on HALO. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. UBS Group reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Trading Up 3.9%

Shares of NASDAQ:HALO opened at $80.84 on Tuesday. The company’s 50-day moving average price is $72.79 and its two-hundred day moving average price is $70.50. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. Halozyme Therapeutics has a one year low of $57.67 and a one year high of $82.26. The stock has a market capitalization of $9.59 billion, a PE ratio of 29.08, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.Halozyme Therapeutics’s revenue for the quarter was up 42.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts forecast that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Insider Activity

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. This trade represents a 33.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the company’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total transaction of $153,397.71. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $61,245,810.60. This represents a 0.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 74,102 shares of company stock valued at $5,205,798 over the last three months. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Wedge Capital Management L L P NC acquired a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $31,607,000. Tema ETFs LLC lifted its holdings in Halozyme Therapeutics by 0.6% during the 2nd quarter. Tema ETFs LLC now owns 32,598 shares of the biopharmaceutical company’s stock worth $2,551,000 after purchasing an additional 210 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in Halozyme Therapeutics by 28.1% in the 2nd quarter. Handelsbanken Fonder AB now owns 631,899 shares of the biopharmaceutical company’s stock valued at $49,459,000 after purchasing an additional 138,430 shares during the period. Focus Financial Network Inc. boosted its stake in Halozyme Therapeutics by 6.7% in the 2nd quarter. Focus Financial Network Inc. now owns 3,651 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 229 shares during the period. Finally, Gradient Investments LLC acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at $1,287,000. 97.79% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.